Discovery Belux: Comparison of rosuvastatin with atorvastatin in hypercholesterolaemia

Acta Cardiologica

Volumn 63, Issue 4, 2008, Pages 493-499

  Herregods, Marie Christine ^a,f   Daubresse, Jean Claude ^b   Michel, Georges ^c   Lamotte, Mark ^d   Vissers, Eugène ^e   Vandenhoven, Guy ^e  

^a UZ   (Belgium)

^b Centre Hospitalier Universitaire de Charleroi   (Belgium)

^c Centre Hospitalier de Luxembourg   (Belgium)

^d IQVIA   (United States)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Atorvastatin; Discovery; Hypercholesterolaemia; Rosuvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BELGIUM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN;

BELGIUM; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HEALTH STATUS INDICATORS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; LOGISTIC MODELS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 52249121180     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.4.2033049     Document Type: Article

References (11)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349 (9063): 1436-42.
2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1-12.
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 2. 933-6.
4. De Backer G, Ambrosioni E, Aorch-Johnsen K, Brotons N, Cifkova R, Dallongeville J, Ebrahim S, Faergeman 0, Graham 1, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl. 1): S2-S78.
5. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
6. Bots AFE, Kastelein JJP; Discovery Netherlands Investiga- tors. Achiev ing lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005, 59: 1387-94.
7. Fonseca FAH, Ruiz A. Cardon-Mu÷noz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators. The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value - an Evaluation of ROsuvastatin theapY compared with atorvastatin. Curr Med Res Opin 2005. 21: 1307-15.
8. Strandberg TE, Feely J, Sigurdsson EL. Discovery Study group. Twelve-week, multicenter, randomised, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10mg/d in high-risk adults: a DISCOVERY study. Clin Aer 2004; 26: 1821-33.
9. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörätä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503.
10. Muls E, Van,Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 (Suppl): S 111-6.
11. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson JG. Safety of rosuvastatin. Am J Cardiology 2004; 94: 882-8.